Viking Therapeutics, Inc.
VKTX
$33.88
-$0.67-1.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -90.79M | -65.56M | -45.63M | -35.42M | -24.94M |
| Total Depreciation and Amortization | 114.00K | 112.00K | 111.00K | 110.00K | 87.00K |
| Total Amortization of Deferred Charges | 8.00K | 24.00K | 24.00K | 24.00K | 24.00K |
| Total Other Non-Cash Items | 5.31M | 11.16M | 8.23M | 1.65M | 3.90M |
| Change in Net Operating Assets | -8.64M | 7.20M | -15.06M | 2.46M | -1.03M |
| Cash from Operations | -94.00M | -47.06M | -52.33M | -31.18M | -21.96M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 160.03M | 42.51M | 63.25M | 6.58M | 25.90M |
| Cash from Investing | 160.03M | 42.51M | 63.25M | 6.58M | 25.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 480.00K | 507.00K | 349.00K | 1.00M | 2.52M |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 480.00K | 507.00K | 349.00K | 1.00M | 2.52M |
| Foreign Exchange rate Adjustments | -6.00K | -12.00K | 1.00K | -74.00K | -29.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 66.50M | -4.06M | 11.26M | -23.67M | 6.43M |